Analyst Price Target is $34.50
▲ +591.38% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Aadi Bioscience in the last 3 months. The average price target is $34.50, with a high forecast of $36.00 and a low forecast of $33.00. The average price target represents a 591.38% upside from the last price of $4.99.
Current Consensus is
The current consensus among 1 contributing investment analysts is to buy stock in Aadi Bioscience. This Buy consensus rating has held steady for over two years.
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus bound to albumin. The company is also involved in evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.